Dimitrios Kontoyiannis, M.D., Sc.D.
- Infectious Disease Research
- Leukemia Research
Invasive fungal infections (IFIs) are leading causes of death in patients with leukemia and hematopoietic cell transplant recipients in our institution. Dimitrios Kontoyiannis, M.D., Sc.D., and his lab team are studying the pathogenesis of IFIs and the development of novel therapeutic strategies against these devastating infections. Antifungal resistance, novel diagnostics and delivery systems and fungal pharmacology are also areas of interest.
Specifically, for the last 18 years, the Kontoyiannis Laboratory has made significant contributions towards establishing the conceptual framework for correlating antifungal resistance with outcome of antifungal therapy, the activity of novel antifungal compounds, and combination therapy. The team has also developed novel experimental Drosophila models to study antifungal therapy and fungal pathogenesis, in vivo pharmacodynamics of antifungals and novel diagnostics. This work has led to several awards and recognitions nationally and internationally.
In terms of his work in clinical mycology, Kontoyiannis has authored numerous studies focusing on the epidemiology, natural history, prognosis and management of virtually every common mycosis that afflicts immunocompromised patients with cancer. He has been extensively involved in the design and implementation of several clinical trials of novel antifungal agents for both the prophylaxis and treatment, and is a member of the writing committee for the IDSA Aspergillus treatment guidelines.